Glembatumumab-Vedotin is an ADC consisting of Glembatumumab, a monoclonal antibody targeted to the extracellular domain of the NMB glycoprotein, which is overexpressed in several tumors including breast cancer [79,80], conjugated to monomethyl auristatin E (MMAE, vedotin) [76]. Here, GPNMB is linked to breast carcinoma.